FC
TEVA icon

Financial Consulate’s Teva Pharmaceuticals TEVA Stock Holding History

Financial Consulate’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Sell
345
-12
-3% -$386 ﹤0.01% 630
2025
Q4 		$11.1K Buy
357
+270
+310% +$6.65K ﹤0.01% 595
2025
Q3 		$1.76K Buy
+87
New +$1.53K ﹤0.01% 798

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Consulate's TEVA Position: Q1 2026 in Review

Financial Consulate reduced its Teva Pharmaceuticals (TEVA) stake by 3.4% in Q1 2026, selling an estimated $386 and leaving 345 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #630.

Financial Consulate first reported a position in TEVA in Q3 2025 and has held it in 3 quarters since. The position peaked at $11.1K in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Financial Consulate held 345 shares of Teva Pharmaceuticals worth $10.4K as of Q1 2026.
  • Financial Consulate sold 12 Teva Pharmaceuticals shares in Q1 2026, an estimated $386.
  • Teva Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #630 holding.
  • Financial Consulate first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Financial Consulate's Teva Pharmaceuticals position peaked at $11.1K in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.